US scientists have developed a potential medication for the genetic cause of ALS and dementia, that eliminates the mutated segments of RNA.
List view / Grid view
Researchers have developed a new method to screen drugs for Alzheimer’s disease, shedding light on why current drugs have failed and identifying novel drug targets.
Researchers have discovered two types of cells in the brain that are involved in organising discrete memories based on when they occurred. This finding improves the understanding of how the human brain forms memories and could have implications in memory disorders such as Alzheimer’s disease.
Researchers have innovated the petri dish to be able to grow and age live brain cells from patients with neurological disorders.
In mice, researchers have shown that δ-valerobetaine plays a role in neurocognitive ability, making the metabolite a target for age-related memory loss.
Dr Antal Szalay, CEO and Founder of Ultimate Medicine, explores how the analysis of omics data, especially metabolomics and proteomics, can provide researchers with vital insight that can inform the development of drugs for conditions associated with age.
Researchers identified three microRNAs whose levels were associated with mental performance in cells, mice and humans.
Guided by precise biomarker tests, therapeutic vaccines targeting the pathology of neurodegenerative disease could provide solutions to the impending global crisis in dementia. As Dr Andrea Pfeifer, Co-Founder, Chief Executive Officer and Director of AC Immune, describes here, current work is both establishing the targets that those vaccines must address…
Two different peptides were found to slow the spread of alpha-synuclein, potentially becoming the first drugs to slow the progression of Parkinson’s disease.
Sphingosine-1 phosphate was found to regulate blood glow in cerebral blood vessels in mice, presenting a potential therapeutic target.
To ensure that new drugs are effective and have as little toxicity as possible, they first need to be tested in model systems before entering clinical trials. In this Q&A, Dr Takanori Takebe outlines his research into liver organoids derived from stem cells that can be used to test new…
Researchers have developed a stem cell therapy that could treat the damage caused by dementia by launching a repair response.
A study has shown that treatments to reduce levels of hydrogen sulphide (H2S) in the brain may help to prevent dementia.
Although many potential targets have been identified for Alzheimer’s disease (AD), there is no effective treatment for this debilitating condition. In this article, Monika Schmidt and Sheraz Gul delve into the key proteins implicated in AD and suggest how phenotypic assays could aid in AD drug discovery.
Scientists have designed a high affinity antibody for pathogenic amyloid beta oligomers, a key driver of Alzheimer’s disease, for use in further research and as a potential diagnostic tool.